Home › Acute Myeloid Leukemia › West Virginia
Pag-aaral pangklinika para sa Acute Myeloid Leukemia sa West Virginia
6 pag-aaral para sa Acute Myeloid Leukemia ang naghahanap ng mga kalahok sa mga site sa West Virginia.
Opisyal na teksto ng pag-aaral (English)
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Edwards Comprehensive Cancer Center, Huntington
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 40 hanggang 75 · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT05334069A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- West Virginia University Charleston Division, Charleston
Nagre-recruitPhase 3
6 Months – 21 Years · Lahat ng kasarian · Na-update Set 17, 2026 · NCT04293562Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
- US-Wheeling WV-WVU, Wheeling
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 2, 2026 · NCT06652438The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- West Virginia University Healthcare, Morgantown
Nagre-recruitPhase 1/2
Hanggang edad 22 · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT04726241Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- WVU Medicine Wheeling Hospital, Wheeling
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 20, 2026 · NCT07007312A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- West Virginia University, Morgantown
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update Hul 6, 2026 · NCT01351545Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.